-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O3.6 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Therapeutic Impact in Multiple Myeloma

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Antibody Therapy, clinical trials, Clinical Practice (Health Services and Quality), Translational Research, Plasma Cell Disorders, Combination therapy, Clinical Research, Diseases, Therapies, real-world evidence, Lymphoid Malignancies, Myeloid Malignancies, Monoclonal Antibody Therapy, Minimal Residual Disease , Transplantation, Vaccines
Monday, December 12, 2022: 10:30 AM-12:00 PM
New Orleans Theater C (Ernest N. Morial Convention Center)
Moderators:
Faith E Davies, MD, NYU Langone Health and Charlotte Pawlyn, PhD, ARRAY(0xf4739c0)
Disclosures:
Pawlyn: Abbvie: Consultancy; Sanofi: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: Travel support; Celgene/BMS: Consultancy, Honoraria.
A look at therapeutic impact of treatments and vaccines in certain populations of MM patients
10:30 AM

Sara Bringhen, MD1, Mattia D'Agostino, MD2,3*, Nicola Giuliani, MD, PhD4, Irene Attucci, MD5*, Renato Zambello, MD6*, Sonia Ronconi, MD7*, Iolanda Donatella Vincelli, MD8*, Alessandro Allegra, MD9*, Giovanna Leonardi, MD10*, Giuseppe Rossi, MD11, Francesco Cattel, MSc12*, Andrea Capra, MScEng3*, Piero Galieni, MD13*, Alessandra Lombardo, MD14*, Francesca Bonello, MD1*, Patrizia Tosi, MD15*, Maide Maria Cavalli, MD, PhD16*, Elisa Sciorsi, MSc12*, Donato Mannina, MD17*, Roberto Ria, MD18*, Francesca Patriarca, MD, PhD19*, Michele Cavo, MD20,21*, Silvia Mangiacavalli, MD22*, Giulia Benevolo, MD1*, Andrea Evangelista, MSc23*, Mario Boccadoro, MD2,3, Benedetto Bruno, MD, PhD2,3* and Alessandra Larocca, MD, PhD1,3

1SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
2Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
3Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
4Hematology, Department of Medicine and Surgery, University of Parma, Parma, Italy
5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
6Department of Medicine (DIMED), Hematology and Clinical Immunology, Padua University, Padua, Italy
7IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
8Hematology Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
9Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", Division of Hematology, University of Messina, Messina, Italy
10U.O.C. Ematologia, Azienda Ospedaliera Universitaria di Modena, Modena, Italy
11Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
12S.C. Farmacia Ospedaliera, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
13U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno, Ascoli Piceno, Italy
14Azienda Ospedaliera Santa Maria di Terni, Terni, Italy
15UO Ematologia, Ospedale di Rimini, Rimini, Italy
16UOSD Ematologia, AULSS 6 Euganea, Osp. Camposampiero, Camposampiero (PD), Italy
17Oncology-Hematology Department, Papardo Hospital, Messina, Italy
18Department of Biomedical Science, University of Bari "Aldo Moro" Medical School, Internal Medicine "G. Baccelli", Policlinico, Bari, Italy
19Hematologic Clinic and Transplant Center, University Hospital of Central Friuli, DAME, University of Udine, Udine, Italy
20IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
21Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
22Department of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
23Unit of Clinical Epidemiology, Città della Salute e della Scienza di Torino, Torino, Italy

10:45 AM

Carlyn Tan, MD1, David Nemirovsky, MS2*, Andriy Derkach, PhD2*, Malin Hultcrantz, MD, PhD1, Hani Hassoun, MD1, Sham Mailankody, MBBS 3, Urvi A Shah, MD1, Dhwani Patel, MD1*, Kylee H Maclachlan, MBBCh, PhD1, Oscar B Lahoud, MD3, Gunjan L. Shah, MD3*, Michael Scordo, MD3, David J. Chung, MD, PhD3, Heather Landau, MD3, Sergio A Giralt, MD3, Alexander M Lesokhin, MD1, Neha Korde, MD1 and Saad Usmani, MD4,5

1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
3Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Levine Cancer Institute, New York, NY
5Memorial Sloan Kettering Cancer Center, New York, NY

11:00 AM

Thierry Facon1*, Philippe Moreau, MD2*, Ross Baker, MBBS, FRACP, FRCPA, BSc3, Ludek Pour, MD, Prof, PhD4*, Chang-Ki Min, MD, PhD5*, Xavier Leleu, MD, PhD6, Mohamad Mohty, MD PhD7, Lionel Karlin8*, Andreea Rawlings9*, Christina Tekle, PhD9*, Sandrine Schwab10*, Marie-Laure Risse10* and Thomas Martin, MD11

1Department of Hematology, Lille University Hospital, Lille, France
2University Hospital Hotel-Dieu, Nantes, France
3Perth Blood Institute, Murdoch University, Perth, Australia
4Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
5Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul, Korea, Republic of (South)
6Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France
7Department of Hematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France
8Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France
9Sanofi, Cambridge, MA
10Sanofi, Vitry-sur-Seine, France
11Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA

11:15 AM

John R Jones, MD1,2,3,4*, David Cairns, PhD5*, Tom Menzies5*, Charlotte Pawlyn, PhD6,7, Faith E. Davies, MD8*, Rachel Sigsworth5*, Matthew W Jenner9*, Martin F. Kaiser, MD, FRCP, FRCPath10,11, Rebecca Mottram, BA, BSc5*, Mark T Drayson, MD12*, Walter Martin Gregory, PhD5*, Roger G Owen13*, Kevin Boyd, PhD11*, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath14*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM15 and Gareth J. Morgan, MD16

1Institute of cancer research, London, United Kingdom
2Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom
3King's College Hospital NHS Foundation Trust, London, United Kingdom
4Eastbourne District General Hospital, Eastbourne, United Kingdom
5Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
6Institute of Cancer Research, Sutton, United Kingdom
7Royal Marsden Hospital, London, United Kingdom
8Perlmutter Cancer Center, NYU Langone, New York, NY
9Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
10The Institute of Cancer Research, Sutton, United Kingdom
11The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
12Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
13St. James's University Hospital, Leeds, United Kingdom
14Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
15Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
16Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

11:30 AM

Julius Christoph Enssle, MD1,2,3*, Alina Moter2,4,5*, Julia Campe2,4,5*, Alec Gessner1,2,3*, Ika Weijia Yu1,2,3*, Sebastian Wolf1,2,3*, Björn Steffen, MD1*, Hubert Serve, MD1,2,6, Melanie Bremm, Dr.7*, Sabine Huenecke, PD Dr.7*, Michael Lohoff, PhD8*, Maria Vehreschild, MD9*, Holger F. Rabenau10*, Marek Widera10*, Sandra Ciesek, MD10,11,12*, Michael A Rieger1,2,3,13*, Katharina Imkeller2,14,15*, Ivana von Metzler, MD1,2,3* and Evelyn Ullrich, MD2,3,4,5,15

1Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe-University, Frankfurt, Germany
2Frankfurt Cancer Institute (FCI), Frankfurt, Germany
3German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Frankfurt, Germany
4Experimental Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
5Division of Pediatric Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
6Goethe University Frankfurt, Frankfurt, Germany
7Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
8Institute of Medical Microbiology and Hospital Hygiene, Philipps University, Marburg, Germany
9Department of Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
10Institute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
11German Centre for Infection Research, External partner site, Frankfurt, Germany
12Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
13Cardio-Pulmonary Institute, Frankfurt, Germany
14Edinger Institute (Neurological Institute), University Hospital Frankfurt, Frankfurt, Germany
15University Cancer Center (UCT), Frankfurt, Germany

11:45 AM

Hiroyuki Takamatsu, MD, PhD1,2, Daisuke Ikeda, MD3*, Toshiki Terao, MD3*, Takeshi Yamashita, MD4*, Ryota Urushihara, MD1*, Yuzuki Hatano1*, Nana Hirose1*, Natsu Yamada4*, Ryoichi Murata, MD4*, Toshihiro Miyamoto, MD, PhD1 and Kosei Matsue, MD, PhD3

1Department of Hematology, Kanazawa University, Kanazawa, Japan
2​School of Entrepreneurial and Innovation Studies, Kanazawa University, Kanazawa, Japan
3Department of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan
4Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan

*signifies non-member of ASH